CPRX - カタリスト・ファ―マシュ―ティカルズ (Catalyst Pharmaceuticals Inc.) カタリスト・ファ―マシュ―ティカルズ

 CPRXのチャート


 CPRXの企業情報

symbol CPRx
会社名 Catalyst Pharmaceuticals Inc (カタリスト・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 カタリスト・ファーマシューティカル(Catalyst Pharmaceuticals Inc. )(旧名:Catalyst Pharmaceutical Partners Inc.)は、開発段階のバイオ医薬品会社である。同社は、希少な衰弱性疾患を患うの人々のための治療法の開発及び商品化に注力する。同社には、「Firdapse」、「CPP-109」及び「CPP-115」の3品目の開発中の薬剤がある。「Firdapse」は、ランバート摂食筋萎縮症候群(LEMS)及び先天性筋無力症候群(CMS)の治療に適応され、amifampridineのリン酸塩から構成される。「Firdapse」の第Ⅲ相試験は完了した。「CPP-109」は、γ-アミノ酪酸(GABA)アミノトランスフェラーゼ阻害剤であり、トゥレット症候群の治療に適応される。「CPP-115」は、GABAアミノトランスフェラーゼ阻害剤であり、複雑な部分発作、トゥレット症候群及びてんかん発作などの神経学的適応症の治療に適応される。   カタリスト・ファ―マシュ―ティカルズは米国の医薬品メ―カ―。神経筋と神経疾患をタ―ゲットとして処方薬の開発と商業化に従事。筋力低下を特徴とする自己免疫疾患であるランバ―ト・イ―トン症候群の治療薬Firdapse、乳児けいれんの治療薬CPP-115、トゥレット症候群治療CPP-109の開発を行う。本社はフロリダ州。   Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.
本社所在地 355 Alhambra Circle Suite 1250 Coral Gables FL 33134 USA
代表者氏名 Patrick James McEnany パトリック・ジェームス・マッケナニー
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 305-529-2522
設立年月日 38899
市場名 NASDAQ Small Cap
ipoyear 2006年
従業員数 21人
url www.catalystpharma.com
nasdaq_url https://www.nasdaq.com/symbol/cprx
adr_tso
EBITDA EBITDA(百万ドル) -22.05182
終値(lastsale) 3.39
時価総額(marketcap) 347811484.62
時価総額 時価総額(百万ドル) 339.60350
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 271.19460
当期純利益 当期純利益(百万ドル) -21.23038
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Catalyst Pharmaceuticals Inc revenues was not reported. Net loss increased 32% to $11.7M. Higher net loss reflects reasear increase of 32% to $6.4M (expense) General and administrative - Balancing increase of 57% to $4.1M (expense) Stock-based Compensation in SGA increase of 23% to $1.2M (expense). Basic Earnings per Share excluding Extraordinary Items remained flat at -$0.11.

 CPRXのテクニカル分析


 CPRXのニュース

   ROCE Insights For Catalyst Pharmaceuticals  2020/08/14 10:30:00 Benzinga
Catalyst Pharmaceuticals (NASDAQ: CPRX) posted a 3.91% decrease in earnings from Q1. Sales, however, increased by 1.61% over the previous quarter to $29.61 …
   Catalyst Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update  2020/08/10 20:15:00 GlobeNewswire
- Firdapse® Second Quarter Net Revenues of $29.6 Million - Health Canada Approves Marketing Authorization for Firdapse® for Treating LEMS Patients -…
   Earnings Preview: Catalyst Pharmaceuticals  2020/08/07 11:11:00 Benzinga
Catalyst Pharmaceuticals (NASDAQ: CPRX) announces its next round of earnings this Monday, August 10. Here is Benzinga's everything-that-matters …
   Here's How Much Investing $1,000 In Catalyst Pharmaceuticals In 2010 Would Be Worth Today  2020/08/04 17:30:11 Benzinga
Investors who owned stocks in the 2010s generally experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY ) total return for the decade was 250.5%. But there’s no question some big-name stocks did much better than others along the way. Catalyst’s Solid Decade: One stock that kept pace over the last decade was biopharmaceutical company Catalyst Pharmaceuticals Inc (NASDAQ: CPRX ). Catalyst Pharmaceuticals develops treatments for rare diseases, such as autoimmune disorder Lambert-Eaton Myasthenic Syndrome (LEMS). The big news for Catalyst in the past decade came in 2018 when the company’s Firdapse became the first LEMS treatment ever approved in the U.S. Firdapse was subsequently approved in Japan … Full story available on Benzinga.com
   Catalyst Pharmaceuticals : 2019 Annual Report | MarketScreener  2020/07/13 07:06:09 MarketScreener
2019 ANNUAL REPORT Dear Shareholders, I am pleased to report that 2019 was a very positive and transformational year for Catalyst and, most… | July 13, 2020
   Here's How Much Investing $1,000 In Catalyst Pharmaceuticals In 2010 Would Be Worth Today  2020/08/04 17:30:11 Benzinga
Investors who owned stocks in the 2010s generally experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY ) total return for the decade was 250.5%. But there’s no question some big-name stocks did much better than others along the way. Catalyst’s Solid Decade: One stock that kept pace over the last decade was biopharmaceutical company Catalyst Pharmaceuticals Inc (NASDAQ: CPRX ). Catalyst Pharmaceuticals develops treatments for rare diseases, such as autoimmune disorder Lambert-Eaton Myasthenic Syndrome (LEMS). The big news for Catalyst in the past decade came in 2018 when the company’s Firdapse became the first LEMS treatment ever approved in the U.S. Firdapse was subsequently approved in Japan … Full story available on Benzinga.com
   Catalyst Pharmaceuticals : 2019 Annual Report | MarketScreener  2020/07/13 07:06:09 MarketScreener
2019 ANNUAL REPORT Dear Shareholders, I am pleased to report that 2019 was a very positive and transformational year for Catalyst and, most… | July 13, 2020
   Catalyst (CPRX) Down 0.4% Since Last Earnings Report: Can It Rebound?  2020/06/10 15:30:45 Zacks Investment Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Catalyst (CPRX) Q1 Earnings Beat Estimates, Revenues Miss  2020/05/12 14:17:00 Zacks Investment Research
Catalyst (CPRX) beats on Q1 earnings but misses on revenues. It also withdraws sales guidance due to the coronavirus pandemic.
   Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings Estimates  2020/05/11 23:25:05 Zacks Investment Research
Catalyst (CPRX) delivered earnings and revenue surprises of 11.11% and -8.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Catalyst Pharmaceuticals : 2019 Annual Report | MarketScreener  2020/07/13 07:06:09 MarketScreener
2019 ANNUAL REPORT Dear Shareholders, I am pleased to report that 2019 was a very positive and transformational year for Catalyst and, most… | July 13, 2020
   Catalyst (CPRX) Down 0.4% Since Last Earnings Report: Can It Rebound?  2020/06/10 15:30:45 Zacks Investment Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Catalyst (CPRX) Q1 Earnings Beat Estimates, Revenues Miss  2020/05/12 14:17:00 Zacks Investment Research
Catalyst (CPRX) beats on Q1 earnings but misses on revenues. It also withdraws sales guidance due to the coronavirus pandemic.
   Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings Estimates  2020/05/11 23:25:05 Zacks Investment Research
Catalyst (CPRX) delivered earnings and revenue surprises of 11.11% and -8.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Catalyst (CPRX) Up 52.1% Since Last Earnings Report: Can It Continue?  2020/04/15 15:30:11 Zacks Investment Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 カタリスト・ファ―マシュ―ティカルズ CPRX Catalyst Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)